Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma × tafasitamab × 90 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Recurrence 2 Lymphoma, Non-Hodgkin 2 Lymphoma, B-Cell 2 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Hodgkin Disease 1 Burkitt Lymphoma 1

Interventions

Cyclophosphamide 25 Rituximab 20 fludarabine 17 Prednisone 14 Biopsy 14 Specimen Handling 10 Magnetic Resonance Spectroscopy 10 Doxorubicin 9 Vincristine 8 Lenalidomide 8 Bendamustine Hydrochloride 8 venetoclax 7 pembrolizumab 7 obinutuzumab 7 fludarabine phosphate 6 Etoposide 6 Mycophenolic Acid 5 Mesna 5 Melphalan 5 Gemcitabine 5 Cytarabine 5 zanubrutinib 4 Whole-Body Irradiation 4 Tacrolimus 4 Sirolimus 4 Oxaliplatin 4 trametinib 3 polatuzumab vedotin 3 glofitamab 3 copanlisib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07030699 2026-03-06

ECLAT

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡